Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

SYRE

Spyre Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1636282Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income FY2025
$(155.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
—
ROE FY2025
-21.7%
Total Equity
$715.0M
Shares Out
88M
Business description

Spyre Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 5 → 0
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022⚑FY2023FY2024FY2025
Revenue55400192100
Research & development(18)(23)(37)(65)(60)(57)(59)———
General & administrative(8)(10)(13)(16)(22)(27)(29)(40)(46)(48)
Total operating expenses(27)(33)(49)(80)(81)(84)(87)(243)(209)(210)
Operating income(22)(28)(45)(80)(81)(66)(85)(242)(209)(210)
Other income (expense), net0012101(97)154
Pre-tax income———(78)(81)(66)(84)(339)(208)(155)
Income tax expense0000000000
Net income(22)(27)(44)(78)(81)(66)(84)(339)(208)(155)
EPS — basic————($1.52)($1.00)($0.99)($49.12)——
EPS — diluted————($1.52)($1.00)($0.99)($49.12)——
Shares outstanding — basic (M)————5366847——
Shares outstanding — diluted (M)————5366847——

Showing the latest 10 of 12 fiscal years.

  • ⚑ Weighted-average shares changed ÷12.50 between FY2022 and FY2023 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.